--- title: "Adlai Nortye Ltd. (ANL.US)" type: "Symbol" locale: "en" url: "https://longbridge.com/en/quote/ANL.US.md" symbol: "ANL.US" name: "Adlai Nortye Ltd." industry: "Biotechnology" datetime: "2026-05-20T14:41:54.932Z" locales: - [en](https://longbridge.com/en/quote/ANL.US.md) - [zh-CN](https://longbridge.com/zh-CN/quote/ANL.US.md) - [zh-HK](https://longbridge.com/zh-HK/quote/ANL.US.md) --- # Adlai Nortye Ltd. (ANL.US) ## Company Overview Adlai Nortye Ltd., a clinical-stage company, together with its subsidiaries, engages in the research and develops pharmaceutical products. Its product pipeline comprises AN0025, a small molecule EP4 antagonist which is in phase Ib and radiotherapy/chemoradiotherapy combination for the treatment of rectum cancer and esophageal cancer; and phase II trial for patients with moderate to high-risk rectal cancer. The company also develops AN9025, an oral small molecule pan-RAS(ON) inhibitor, which is in phase 1a clinical trials for the treatment of RAS-mutant cancers, including pancreatic, lung, and colorectal adenocarcinomas; AN4035, a proprietary CEACAM5-targeting antibody drug conjugate designed to deliver potent anti-tumor activity with an improved therapeutic window; and AN8025, a tri-specific antibody fusion protein which is in phase Ia clinical trial to treat advanced tumors. In addition, it develops AN4005, a small-molecule PD-L1 inhibitor that demonstrates antitumor activity by the blockade of PD-1/PD-L1 interaction which is in phase 1b clinical trial to activate cancer immunity. | Item | Detail | |------|--------| | Industry | Biotechnology | | Exchange | US Market | | Website | [www.adlainortye.com](https://www.adlainortye.com) | ## Key Drivers > *AI-analyzed key factors driving this stock's performance* ## Longbridge Financial Score™: D > *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge* > Updated: 2026-05-20T04:30:16.000Z **Overall: D (0.75)** **Industry**: Biotechnology | Metric | Value | |--------|-------| | Industry Ranking | 236 / 386 | | Industry Median | C | | Industry Average | C | - **Style**: Value - Stocks where the company's main business is in a mature stage. - **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns. **Multi Score**: D #### Style Score Score: | Indicator | Value | Rating | |-----------|-------|--------| | Revenue YoY | 0.00% | | | Net Profit YoY | 31.50% | | | P/B Ratio | -51.43 | | | Dividend Ratio | 0.00% | | #### Size Score Score: | Indicator | Value | Rating | |-----------|-------|--------| | Market Cap | 427960056.90 | | | Revenue | 5000000.00 | | #### Multi Score Score: D | Indicator | Value | Rating | |-----------|-------|--------| | ROE | -414.01% | E | | Profit Margin | -710.56% | E | | Gross Margin | 100.00% | A | | Revenue YoY | 0.00% | D | | Net Profit YoY | 31.50% | B | | Total Assets YoY | -51.69% | E | | Net Assets YoY | -132.65% | E | | Cash Flow Margin | 94.16% | C | | OCF YoY | 0.00% | D | | Turnover | 0.09 | E | | Gearing Ratio | 124.17% | E | ```chart-data:radar { "title": "Longbridge Financial Score - Adlai Nortye Ltd.", "chart_type": "radar", "dimensions": [ { "name": "Style Score", "grade": "", "indicators": [ { "name": "Revenue YoY", "value": "0.00%", "rating": "" }, { "name": "Net Profit YoY", "value": "31.50%", "rating": "" }, { "name": "P/B Ratio", "value": "-51.43", "rating": "" }, { "name": "Dividend Ratio", "value": "0.00%", "rating": "" } ] }, { "name": "Size Score", "grade": "", "indicators": [ { "name": "Market Cap", "value": "427960056.90", "rating": "" }, { "name": "Revenue", "value": "5000000.00", "rating": "" } ] }, { "name": "Multi Score", "grade": "D", "indicators": [ { "name": "ROE", "value": "-414.01%", "rating": "E" }, { "name": "Profit Margin", "value": "-710.56%", "rating": "E" }, { "name": "Gross Margin", "value": "100.00%", "rating": "A" }, { "name": "Revenue YoY", "value": "0.00%", "rating": "D" }, { "name": "Net Profit YoY", "value": "31.50%", "rating": "B" }, { "name": "Total Assets YoY", "value": "-51.69%", "rating": "E" }, { "name": "Net Assets YoY", "value": "-132.65%", "rating": "E" }, { "name": "Cash Flow Margin", "value": "94.16%", "rating": "C" }, { "name": "OCF YoY", "value": "0.00%", "rating": "D" }, { "name": "Turnover", "value": "0.09", "rating": "E" }, { "name": "Gearing Ratio", "value": "124.17%", "rating": "E" } ] } ] } ``` ## Valuation Analysis | Metric | Current | Industry Ranking | High | Median | Low | |--------|---------|-----------------|------|--------|-----| | PE (TTM) | -12.05 | 472/386 | - | - | - | | PB | -51.43 | 540/386 | 32.23 | 2.46 | 2.19 | | PS (TTM) | 85.59 | 250/386 | 119.43 | 110.87 | 101.02 | | Dividend Yield | 0.00% | - | - | - | - | ## Peer Comparison | Rank | Name | Profit | Growth | Operation | Security | Cash | Rating | | --- | --- | --- | --- | --- | --- | --- | --- | | 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A | | 02 | Arbutus Pharma (ABUS.US) | A | A | A | A | B | A | | 03 | Rigel Pharma (RIGL.US) | A | A | B | A | B | A | | 04 | Spero Therap (SPRO.US) | A | A | B | A | B | A | | 05 | CapForce Inc. (CFOR.US) | B | A | A | A | B | A | ## Institutional View ### Analyst Rating Distribution > As of 2026-05-14T04:00:00.000Z Total Analysts: **4** | Rating | Count | Percentage | |--------|-------|-----------| | Buy | 4 | 100% | ### Target Price Forecast | Metric | Price | |--------|-------| | Current Price | 10.73 | | Highest Target | 46.00 | | Lowest Target | 20.00 | ## References - [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/ANL.US/overview.md) - [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/ANL.US/norm.md) - [Related News](https://longbridge.com/en/quote/ANL.US/news.md) - [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/ANL.US/filings.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**